Know Labs(US:KNW)2019-08-07 20:16Technology Development - The company is focused on the commercialization of its Bio-RFID technology, which has shown the ability to non-invasively ascertain blood glucose levels in humans [133]. - The first product utilizing Bio-RFID technology will be the UBAND™, a Continuous Glucose Monitor that will provide real-time blood glucose information via Bluetooth connectivity [133]. - Laboratory testing has demonstrated a high degree of correlation between the Bio-RFID technology and leading continuous glucose monitors from Abbott Labs and DexCom [134]. - The company plans to pursue FDA approval for the UBAND™ product during the calendar year 2019, with a dedicated Medical and Regulatory Advisory Board established to guide the process [135]. - The ChromaID technology utilizes low-cost LEDs to create unique signatures for substances, allowing for accurate identification and diagnosis [126][131]. - The ChromaID Reference Library is anticipated to become a significant asset, providing valuable information across various fields of use [132]. - The company has engaged a manufacturing partner to assist in bringing the UBAND™ product to market [155]. - The company is actively pursuing a patent strategy to expand its intellectual property portfolio in the United States and internationally [154]. - The company has 13 patents granted and several pending, with expiration dates ranging from 2027 to 2034, covering fundamental aspects of its ChromaID and Bio-RFID technologies [139][140]. Financial Performance - Net revenue for the three months ended June 30, 2019 decreased by $726,000 to $381,000, a decline of 65.6% compared to $1,107,000 for the same period in 2018 [169]. - Gross profit for the three months ended June 30, 2019 was $105,000, representing a gross margin of 23.4%, compared to $197,000 and a margin of 20.1% in the prior year [171]. - Research and development expenses increased by $316,000 to $442,000 for the three months ended June 30, 2019, primarily due to expenditures related to the development of Bio-RFID technology [172]. - Net loss for the three months ended June 30, 2019 was $805,000, compared to a net loss of $506,000 for the same period in 2018, reflecting a 59.1% increase in losses [178]. - For the nine months ended June 30, 2019, net revenue decreased by $1,855,000 to $1,577,000, a decline of 54.1% compared to $3,432,000 for the same period in 2018 [182]. - Total other income for the three months ended June 30, 2019 was $329,000, compared to $226,000 in the same period in 2018, an increase of 45.6% [176]. - The company incurred research and development expenses of $833,000 for the nine months ended June 30, 2019, an increase of 127.0% compared to $367,000 for the same period in 2018 [181]. - The operating loss for the three months ended June 30, 2019 was $1,134,000, a 203.3% increase from the operating loss of $732,000 in the same period in 2018 [168]. - Gross profit for the nine months ended June 30, 2019 was $374,000, a decrease from $672,000 for the same period in 2018, with gross profit margin increasing to 23.7% from 19.6% [184]. - Research and development expenses increased by $466,000 to $833,000 for the nine months ended June 30, 2019, primarily due to the development of Bio-RFID™ technology [185]. - Selling, general and administrative expenses rose by $1,369,000 to $3,165,000 for the nine months ended June 30, 2019, driven by increased corporate development and stock-based compensation expenses [186]. - Net loss for the nine months ended June 30, 2019 was $3,299,000, compared to a net loss of $2,334,000 for the same period in 2018, with net loss from operations at $81,000 [190]. - As of June 30, 2019, the company had cash of approximately $2,689,000 and a net working capital deficit of approximately $1,228,000 [194]. - Net cash used in operating activities for the nine months ended June 30, 2019 was $2,307,000, primarily due to the net loss and working capital changes [201]. - Net cash provided by financing activities for the nine months ended June 30, 2019 was $4,243,000, mainly from the issuance of common stock for cash [203]. - The company expects losses to continue as it commercializes its ChromaID and Bio-RFID technologies [180]. - The company has focused on maximizing profits at lower sales levels, particularly through its TransTech subsidiary [169]. - The financial results from the TransTech subsidiary have been diminishing, and it is expected to wind down completely before the end of the current fiscal year [127]. - As of June 30, 2019, there were vested warrants totaling 16,573,772 with an aggregate intrinsic value of $15,949,833 [200]. - The company expects to continue incurring losses as it commercializes its ChromaID™ and Bio-RFID™ technologies [192]. Corporate Strategy - The company has engaged a manufacturing partner to assist in bringing the UBAND™ product to market [155]. - The company plans to pursue FDA approval for the UBAND™ product during the calendar year 2019, with a dedicated Medical and Regulatory Advisory Board established to guide the process [135].